恶性胸膜间皮瘤化疗抵抗机制研究进展  

Research Progress on Molecular Mechanism Underlying Chemotherapy Resistance of Malignant Pleural Mesothelioma

作　　者：张利 于杰 陈瑜 罗小迪 汪继翠 涂东 ZHANG Li;YU Jie;CHEN Yu;LUO Xiaodi;WANG Jicui;TU Dong(Department of Cardiothoracic Surgery,the 920th Hospital of Joint Logistics Support Force,Kunming 650032,China)

机构地区：[1]解放军联勤保障部队第920医院心胸外科,昆明650032

出　　处：《肿瘤防治研究》2024年第8期690-696,共7页Cancer Research on Prevention and Treatment

基　　金：云南省科技厅科技计划项目(202101AY070001-303)。

摘　　要：恶性胸膜间皮瘤(MPM)是一种发病率不高,但侵袭性强、预后差、致死率高的肿瘤,生存期为4个月~1年,5年生存率仅为10%左右。MPM具有很强的化疗抵抗性,顺铂联合培美曲塞或者雷替曲塞的常规治疗只在20%左右患者中有一定的效果。近年来,随着对MPM遗传特征研究的不断深入,对MPM化疗抵抗分子机制的研究也取得一定进展。本文总结了近年来MPM化疗抵抗分子机制的研究进展,包括BAP1基因突变、MicroRNA、MTA1介导的DNA损伤修复通路、GITR-GITRL通路、TGFa通路、肿瘤干细胞、EGFR、PTEN等,旨在为探索MPM新治疗靶点、新联合治疗方案提供参考。Malignant pleural mesothelioma(MPM)is a rare,highly aggressive,and lethal tumor with poor prognosis.Its survival period ranges from four months to one year,and the 5-year survival rate is only about 10%.MPM is highly resistant to chemotherapy,and conventional treatments such as cisplatin combined with pemetrexed or raltitrexed only have a certain effect in about 20%of patients.In recent years,with the continuous in-depth understanding of the genetic variation characteristics of MPM,some progress has been made in the molecular mechanism underlying the chemotherapy resistance of MPM.This article will summarize the research progress of the molecular mechanism underlying the chemotherapy resistance of MPM,including BAP1 gene mutation,microRNA,MTA1-mediated DNA damage repair pathway,GITRGITRL pathway,TGFa pathway,tumor stem cell,EGFR,and PTEN.The aim of this work is to provide a reference for exploring new therapeutic targets and combined treatment options for MPM.

关 键 词：恶性胸膜间皮瘤 化疗抵抗 分子机制 

分 类 号：R734.3[医药卫生—肿瘤]